General
Preferred name
treprostinil
Synonyms
UT-15 ()
Treprostinil Sodium ()
Remodulin ()
Treprostinil (sodium) ()
TREPROSTINIL DIOLAMINE ()
UT-15 (sodium) ()
UT-15, Remodulin, Orenitram, Tyvaso, Trevyent ()
Treprostinil diethanolamine ()
Orenitram ()
UT-15C ()
Treprostinil diolamin ()
LRX-15 ()
15AU81 ()
Rumodolin ()
Tresprostinil ()
L-606 ()
Tyvaso dpi ()
15-AU-81 ()
LRX -15 ()
Uniprost ()
Tyvaso ()
Treprostinil (diethanolamine salt) ()
P&D ID
PD010219
CAS
289480-64-4
81846-19-7
830354-48-8
Tags
natural product
drug
available
Approved by
PMDA
EMA
FDA
First approval
2013
2002
Drug Status
investigational
approved
Drug indication
Pulmonary arterial hypertension
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
METABOLISM Substantially metabolized by the liver, but the precise enzymes responsible are unknown. Five metabolites have been described (HU1 through HU5) however, the biological activity and metabolic fate of these are unknown. The chemical structure of HU1 is unknown. The metabolite HU5 is the glucuronide conjugate of treprostinil. The other metabolites are formed by oxidation of the 3-hydroxyoctyl side chain (HU2) and subsequent additional oxidation (HU3) or dehydration (HU4). Study results of in vitro human hepatic cytochrome P450 demonstrates that treprostinil does not inhibit CYP-1A2, 2C9, 2C19, 2D6, 2E1, or 3A. There have been no studies that evaluate the potential of treprostinil to induce these enzymes.
DESCRIPTION Marketed formulations may contain treprostinil diolamine (PubChem CID 11179459) or treprostinil sodium (PubChem CID 23663413). (GtoPdb)
DESCRIPTION Potent and selective GPR39 agonist (Tocris Bioactive Compound Library)
Compound Sets
26
AdooQ Bioactive Compound Library
A13719
A21046
Cayman Chemical Bioactives
11927
10162
ChEMBL Approved Drugs
CHEMBL2107815
CHEMBL1237119
ChEMBL Drugs
CHEMBL2107815
CHEMBL1237119
Concise Guide to Pharmacology 2017/18
5820
Concise Guide to Pharmacology 2019/20
5820
Concise Guide to Pharmacology 2021/22
5820
Concise Guide to Pharmacology 2023/24
5820
Drug Repurposing Hub
DrugBank
DB00374
DrugBank Approved Drugs
DB00374
DrugCentral
2720
DrugCentral Approved Drugs
2720
DrugMAP
DMTIQF3
DrugMAP Approved Drugs
DMTIQF3
EU-OPENSCREEN Bioactive Compound Library
EOS100648
Guide to Pharmacology
5820
Mcule NIBR MoA Box Subset
MCULE-1786426561
MedChem Express Bioactive Compound Library
HY-100441
HY-16504
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
RUM6K67ESG
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
treprostinil-sodium
TargetMol Bioactive Compound Library
T5171
Tocris Bioactive Compound Library
5349
External IDs
66
Properties
(calculated by RDKit )
Molecular Weight
390.24
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
10
Ring Count
3
Aromatic Ring Count
1
cLogP
3.58
TPSA
86.99
Fraction CSP3
0.7
Chiral centers
5.0
Largest ring
6.0
QED
0.53
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Angiogenesis
Tyrosine Kinase/Adaptors
Apoptosis
Target
DP1, IP, EP2
VEGFR2
RET
P2RY12, PPARD, PTGIR
Primary Target
Prostanoid Receptors
MOA
Agonist
Prostaglandin Receptor
Prostacyclin Analogs
prostanoid receptor agonist
Member status
member
Indication
pulmonary arterial hypertension (PAH)
Biosynthetic Origin
Fatty Acid (Eicosanoid)
Therapeutic Indication
Antihypertensive
Therapeutic Class
Cardiovascular
Antihypertensive Agents
Source data